http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Merck (MRK) Says it Won't Submit Applications for Regulatory Approval for Anacetrapib
-
Merck Provides Update on Anacetrapib Development Program
-
Merck (MRK) Announces Six-year Efficacy Data for GARDASIL 9 Presented at EUROGIN 2017 Congress
-
Six-year Efficacy Data for GARDASIL® 9 Presented at EUROGIN 2017 Congress
-
Merck (MRK) Reports 40 Data Presentations at ID Week 2017
-
Merck Highlights Ongoing Commitment to Fighting Infectious Diseases With 40 Data Presentations at ID Week 2017
-
Merck (MRK) to Present New Data on ZEPATIER for Treatment of Chronic HCV Infection at The Liver Meeting
-
Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Infection at The Liver Meeting® 2017
-
Merck (MRK) to Discontinue MK-3682B and MK-3682C Development Programs for HCV
-
Merck (MRK) Says New and Updated Data on KEYTRUDA to Be Presented at WCLC
-
Merck Discontinues MK-3682B and MK-3682C Development Programs
-
New and Updated Clinical Data on Merck’s KEYTRUDA® (pembrolizumab) to Be Presented at 18th World Conference on Lung Cancer
-
Merck Animal Health Extends Commitment to Fighting Rabies in the World’s Most At-Risk Regions
-
Merck to Hold Third-Quarter 2017 Sales and Earnings Conference Call on October 27
-
Merck (MRK) Says FDA Approves KEYTRUDA for Recurrent Metastatic Gastric or GEJ Cancer Whose Tumors Express PD-L1
-
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (
-
Merck KGaA, Pfizer (PFE) Report European Commission Approval for Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
-
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
-
Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly and Leading Cancer Organizations To Expand Your Cancer Game Plan To Help More People Impacted by Cancer
-
Merck (MRK) Says Phase 3 Study of KEYTRUDA Compared to Standard of Care in Patients with Previously Treated HNSCC Didn't Meet Primary Endpoint
-
Merck Announces Findings from Phase 3 Study of KEYTRUDA® (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcino
-
Merck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance
-
Incyte (INCY) Reports Progression-Free Survival Data from ECHO-202 Trial of Epacadostat in Combination with Merck (MRK) KEYTRUDA (pembrolizumab)
-
Merck’s KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Pos
-
Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melano
-
Merck (MRK) Reports KEYTRUDA (pembrolizumab) plus Pemetrexed & Carboplatin (pem/carbo) Demonstrated Continued Benefit
-
Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in P
-
Merck (MRK) Says Updated Data for KEYTRUDA in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO
-
Updated Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress
-
Dr. Sam Bozzette Joins Premier Inc. to Lead Its Research Division
-
Merck to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
-
Merck (MRK) to Acquire Rigontec
-
Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology
-
Merck (MRK) Says EC Approved KEYTRUDA for Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
-
Merck (MRK) Presented New & Updated Data for KEYTRUDA (pembrolizumab) from Extensive Immuno-Oncology Program
-
New and Updated Data for KEYTRUDA® (pembrolizumab) from Merck’s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress
-
Merck (MRK) Reports Results of REVEAL Outcomes Study of Anacetrapib
-
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease
-
AstraZeneca (AZN), Merck (MRK) Confirm LYNPARZA Received Additional and Broad Approval in U.S. for Ovarian Cancer
-
LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer
-
President Trump Announces End of Strategic & Policy Forum and Manufacturing Council on Twitter
-
Trump yields to pressure, calls neo-Nazis and KKK criminals
-
Merck Announces Second-Quarter 2017 Financial Results
-
Pre-Open Stock Movers 07/27: (CAPR) (SHOR) (FB) Higher; (CUR) (AZN) (CYH) Lower (more...)
-
Mandy Moore and Merck Encourage Women to Plan Ahead in Her Life. Her Adventures. Campaign
-
REPEAT/AstraZeneca and Merck Establish Strategic Oncology Collaboration
-
AstraZeneca and Merck Establish Strategic Oncology Collaboration
-
Merck Announces Fourth-Quarter 2017 Dividend
-
Merck (MRK) Announces Doravirine Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection
